Eli Lilly Pauses India Obesity Awareness Campaign Following Regulatory Review Over Prescription Drug Promotion

Eli Lilly and Company has temporarily halted its obesity awareness campaign in India after concerns raised by the country’s drug regulator regarding possible indirect promotion of prescription medicines.

Lilly Suspends “We Know Now” Campaign

According to Reuters, Eli Lilly launched its “We Know Now” campaign in mid-2025 with the aim of increasing awareness about obesity as a chronic medical condition rather than a lifestyle issue.

The campaign reportedly included newspaper advertisements, digital promotions, outdoor billboards, social media engagement and collaborations with public personalities. While the company branding was visible in the campaign material, the obesity treatment Mounjaro was not directly mentioned.

Reuters reported that Lilly informed India’s Drugs Controller General in an April 10 letter that it had paused the campaign following regulatory guidance issued in March.

Regulatory Concerns Over Indirect Promotion

India’s drug regulations prohibit direct-to-consumer advertising of prescription medicines across media platforms. According to Reuters, the regulator cautioned that indirect or surrogate promotion capable of creating brand recall may also be treated as a violation.

The advisory reportedly stated that awareness campaigns, influencer partnerships or promotional activities linked to prescription products could fall under regulatory scrutiny if they indirectly increase consumer visibility of a medicine.

Sources cited by Reuters indicated that authorities also questioned the timing of the campaign, as it coincided with the launch of Mounjaro in India.

Lilly Seeks Greater Regulatory Clarity

In its communication to the regulator, Lilly stated that the awareness initiative was intended to encourage informed discussions around obesity and promote consultation with healthcare professionals, Reuters reported.

The company reportedly argued that suspending the campaign may unintentionally limit scientifically driven public health communication on obesity, particularly as awareness around the condition continues to evolve in India.

Lilly has also sought clearer guidance from authorities regarding the distinction between disease awareness campaigns and indirect product promotion.

Read More: Lupin Share Price in Focus After Signing Semaglutide Agreement With Galenicum Health, Spain.

Want to track these market movements in Hindi? Visit Angel One News for daily updates and comprehensive share market news in Hindi.

Conclusion

Eli Lilly’s decision to pause its obesity awareness campaign highlights the regulatory complexities surrounding healthcare communication and prescription medicine promotion in India.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.